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Running title: Triamterene selectively targets MMR-deficient cells 
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Statement of translational relevance 
Loss of the DNA mismatch repair (MMR) pathway is a common feature of many tumor 
types. Due to the role of MMR proteins in the recognition of many drug-induced DNA 
adducts, MMR-deficient tumors are often resistant to a large number of currently used 
chemotherapies. Therefore, new selective therapies are urgently required for these 
patients. This manuscript reports the identification of a novel therapeutic strategy for the 
treatment of MMR-deficient tumors. We have shown that treatment with the diuretic drug 
Triamterene sensitizes MMR-deficient tumors in vitro and in vivo. This selectivity is 
through a Triamterene-mediated antifolate activity, dependent on thymidylate synthase 
expression. Given the frequency of MMR defects in a range of different tumor types, the 
implication of our work is that Triamterene may be used therapeutically to exploit this 

















Purpose: The DNA Mismatch repair (MMR) pathway is required for the maintenance of 
genome stability. Unsurprisingly, mutations in MMR genes occur in a wide range of 
different cancers. Studies thus far have largely focused on specific tumor types or MMR 
mutations, however it is becoming increasingly clear that a therapy targeting MMR-
deficiency in general would be clinically very beneficial.  
Experimental Design: Based on a drug-repositioning approach, we screened a large 
panel of cell lines with various MMR deficiencies from a range of different tumor types 
with a compound drug library of previously approved drugs. We have identified the 
potassium-sparing diuretic drug Triamterene, as a novel sensitizing agent in MMR-
deficient tumor cells, in vitro and in vivo.  
Results: The selective tumor cell cytotoxicity of Triamterene occurs through its antifolate 
activity, and depends on the activity of the folate synthesis enzyme, thymidylate 
synthase. Triamterene leads to a thymidylate synthase-dependent differential increase in 
reactive oxygen species in MMR-deficient cells, ultimately resulting in an increase in 
DNA double strand breaks.  
Conclusion: Conclusively, our data reveal a new drug repurposing and novel therapeutic 
strategy that has potential for the treatment of MMR-deficiency in a range of different 










Germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSHβ, 
MSH6 and PMSβ can lead to Lynch Syndrome, an autosomal condition also known as 
hereditary non polyposis colorectal cancer (HNPCC)(1). Patients with this condition have 
an 80% lifetime risk of developing colorectal cancer and a 60% lifetime risk of 
developing endometrial cancer. In addition, patients are also at an increased risk of 
developing other cancers such as small bowel, pancreatic, prostate, urinary tract, liver, 
kidney, and bile duct cancer. Defects in the MMR system can also occur as a result of 
somatic mutations or epigenetic silencing. Significantly, it is thought that 15% of all 
colorectal cancers and γ0% of all endometrial cancers have loss of a functional MMR 
pathway (2, 3). Furthermore, mutations in the MMR gene, MSH6 have been identified in 
β6-41% of temozolomide-resistant glioblastoma (GBM) patients and mediate 
temozolomide resistance (4-6). More recently, a number of studies have shown that a 
reduction in MMR protein levels, in particular MSHβ and MSH6, occurs upon GBM 
recurrence and that transcript levels of MMR genes are prognostic for patient survival 
after temozolomide treatment (6-8). 
 
Synthetic lethality with loss of DNA repair proteins has previously been successfully 
exploited (9-13). To date, a number of studies have identified synthetic lethal interactions 
with specific MMR gene mutations or specific tumor types (9, 10, 14, 15). In this study, 
we carried out drug-repositioning compound screens in a panel of MMR-deficient cellular 
models from a range of different tumor types, to identify drugs that sensitize with MMR 
loss in general. We identified the potassium-sparing diuretic drug, Triamterene as a 
novel therapeutic agent in MMR-deficient tumor cells. Our data suggest that the 
selectivity of Triamterene is based on its anti-folate activity and is dependent on 
expression of the folate synthesis enzyme, thymidylate synthase. Taken together, our 
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data reveals that Triamterene is a promising novel therapeutic strategy for the treatment 


























Materials and Methods 
 
Cell lines 
The Uβ51.TRγ GBM cell lines were a kind gift from Dr. David Louis (Massachusetts 
General Hospital, MA, USA). In the original paper (5), the nomenclature for these cell 
lines was A17β.TRγ. In a subsequent correction to the paper, this nomenclature was 
updated to Uβ51.TRγ (MSH6-) (16). We have STR profiled these cell lines and confirm 
they originate from Uβ51 cells. The Uβ51 (MMR+), MFE-β80 (MMR+), MFE-β96 (MLH1-
), KLE (MMR+), ANγCA (MLH1-), HEC1B (MSH6-), RL95-β (MSHβ-, MSH6-, MSHγ-) 
and ISHIKAWA (MLH1-) cell lines were purchased from ATCC. The colorectal DLD1 
(MSH6-) and DLD1+Chrβ (MMR+) cell lines and endometrial HEC59 (MSHβ-) cell lines 
were a kind gift from Dr. Thomas Kunkel (National Institute of Environmental Health 
Sciences). The human colon cancer cell line HCT116 (MLH1-) and HCT116+Chrγ 
(MMR+) were a kind gift from Dr. Alan Clark (NIEHS). DLD1 and DLD1+Chrβ cells were 
grown in RPMI (Sigma-Aldrich), 10% FBS and 1% penicillin-streptomycin at γ7 °C with 
5% COβ. All other cell lines were grown in DMEM (Sigma-Aldrich), 10% FBS and 1% 
penicillin-streptomycin at γ7 °C with 5% COβ. DLD1+Chrβ and HCT116+Chrγ cells were 
maintained under selective pressure of 400 µg/mL geneticin (G418 sulfate, Roche). 
Uβ51.TRγ cells were maintained in 100 µM TMZ (Santa Cruz). All cell lines were 
authenticated on the basis of STR-profile, viability, morphologic inspection, and were 
routinely mycoplasma tested.  
 
Compound Library Screen 
The FDA-approved compound library incorporating 11β0 drugs was purchased from 
Selleck Chemicals. Cells were plated in 96-well plates and treated with vehicle (0.01% 
DMSO) or the compound library (average compound concentration of the library in 
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media was 10 µM). After 4 days incubation with the drug library, cell viability was 
assessed using the CellTiter Glo assay (Promega) according to the manufacturer’s 
instructions. Luminescence readings from each well were log transformed and 
normalized according to the median signal on each plate and then standardized by use 
of a Z-score statistic, using the median absolute deviation to estimate the variation in 
each screen. Z-scores were compared to identify compounds that cause selective loss 
of viability in MMR-deficient cells, in comparison to MMR-proficient cells. For validation 
experiments, cells were treated with increasing concentrations of Triamterene and cell 
viability using the CellTiter Glo assay was assayed after 5 days. Triamterene was 
purchased from Sigma-Aldrich. N-acetyl cysteine was purchased from Santa Cruz.  
 
Colony formation assay 
Validation of Triamterene was performed by colony formation assays. Cells were seeded 
at various densities in six‐well plates and exposed to the drug at the indicated 
concentrations. Cells were retreated every four days, whereby the drug containing media 
was removed and the fresh drug containing media was added. After ten to fourteen 
days, cells were fixed and stained with sulphorhodamine‐B (Sigma, St. Louis, USA) and 
counted.  
 
Cell Cycle Analysis 
Following Triamterene treatment, cells were fixed in 70% ice-cold ethanol and stained 
with 4% propidium iodide (PI) and 10% RNase A in PBS for cell-cycle analysis. The 
sample readout was performed on the BD LSRFortessa (Becton Dickinson, USA), and 




DLD1 and DLD1+Chrβ cell lines (1.6 x 106 cells) re-suspended in PBS, were injected 
subcutaneously into the right flank of adult (~10 weeks old) male NOD-SCID mice 
(Charles-River Laboratories). Tumors were allowed to develop to a mean tumor 
diameter between 4 and 8 mm before treatment. Mice were then treated γ times a week 
by gavage, with β5 mg/kg Triamterene or vehicle. Tumors were measured twice weekly. 
Mice were sacrificed in case of sickness or when the tumors reached 1.44cmβ. All animal 
procedures were carried out as per the Animal Scientific Procedures Act 1986, under the 
Home Office approval licenses (PPL-70/7β75 and PIL-70/βγ444).  
 
Protein analysis  
Cell pellets were lysed in β0 mM Tris (pH 8), β00 mM NaCl, 1 mM EDTA, 0.5% (v/v) 
NP40, 10% glycerol, supplemented with protease inhibitors. For western blotting, lysates 
were electrophoresed on Novex precast gels (Invitrogen) and immunoblotted using the 
following antibodies: anti-MSH6 (#54β4), anti-MSHβ (#β017), anti-MLH1 (#4β56), anti-
thymidylate synthase (#9045), β-Actin (#4970), purchased from Cell Signaling. The 
following antibodies were also used; anti-MSHγ (sc-11441; Santa Cruz) and anti β-
tubulin (T8γβ8; Sigma). This was followed by incubation with anti-IgG-horseradish 
peroxidase and chemiluminescent detection (Supersignal West Pico Chemiluminescent 




For siRNA transfections, cells were transfected with individual siRNA oligos (Qiagen) 
using Lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s instructions. 
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As a control for each experiment, cells were left un-transfected or transfected with a non-
targeting control siRNA and concurrently analyzed.  
 
Reactive Oxygen Species Detection 
Cellular ROS was measured using DCFDA-Cellular Reactive Oxygen Species Detection 
Assay Kit (Abcam, ab11γ851) according to the manufacturer’s instructions. Briefly, to 
detect ROS levels, non-fluorescent β’,7’-dichlorofluorescein diacetate (DCFDA) is 
converted to fluorescent DCF upon ROS (HβOβ, •OH, ONOO- and •Oβ-) induction. Cells 
were plated in clear bottom black 96-well plates and treated with Triamterene for the 
indicated times. Cells were then treated with β0 たM DCFDA or incubated in assay buffer 
as a negative control. After γ0 min incubation at γ7˚ C, cells were washed with 1X PBS 
and incubated for 4 h in fresh assay buffer at γ7˚ C in a 5% COβ incubator. Fluorescence 
was measured, using the Wallac 14β0 plate reader (PerkinElmer). Each assay condition 
was performed in duplicate and cell viability was measured in replicate plates using the 
CellTiter-Glo assay. Fluorescence DCF values were normalized to the corresponding 
cell viability luminescence data. 
 
Detection of cellular DNA damage by Comet assay 
A commercially available Comet assay kit from Cell Biolabs (STA-γ51) was used to 
measure levels of cellular DNA damage. The assays were performed according to the 
manufacturer's instructions. Briefly, 1 x 105 cells were mixed with molten agarose. DNA 
from embedded cells was then denatured in an alkaline solution. Samples were 
electrophoresed in a horizontal chamber to separate intact DNA from damaged 
fragments. Following electrophoresis, samples were then stained with a Vista Green 
DNA dye, and visualized by fluorescence microscopy. Cellular DNA damage is 
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visualised as it migrates further than intact DNA and results in a comet tail shape. For 
assessment of the Comet assay, 50 comets were scored per condition and ImageJ was 
used to quantify the intensity and score the comets using the following calculation: Tail 
DNA % = 100 X Tail DNA Intensity/Cell DNA intensity. 
 
Estimation of 8‐oxodG levels 
A commercially available ELISA kit from Cell Biolabs (STA-γβ0) was used to measure 
levels of 8฀oxodG. Although this 8-oxodG ELISA has potential shortcomings for the 
precise quantification of 8-oxodG levels, it allows an estimation of the change of 8-
oxodG levels upon triamterene treatment. Genomic DNA was extracted using the QIamp 
DNA isolation kit (Qiagen), digested with nuclease P1, treated with calf intestinal 
phosphatase and denatured. To avoid artifactual production of 8-oxodG, we used a 
phenol-free method of DNA isolation and DNA was completely digested. The assays 
were performed according to the manufacturer's instructions. Briefly, 10-15鳥µg DNA from 
untreated and treated cells or the 8฀oxodG standard (0.078–β0鳥ng/ml) was incubated 
with an 8฀oxodG monoclonal antibody in an 8฀oxodG-precoated microtiter plate. The 
assay was normalized by using an equal amount of DNA for each sample. Standard 
curves were calculated with serial dilutions of 8฀oxodG standard to calculate reaction 
efficiency. Samples were assayed in triplicate. 
 
Detection of γH2AX Foci by immunofluorescence 
Cells were seeded onto poly-lysine coated coverslips and treated with drugs as 
indicated. After 48 hrs treatment, cells were fixed for 10 min with 4% PFA in PBS. Cells 
were then permeabilized with Triton, blocked for 1 h at room temperature and 
subsequently incubated with γHβAX antibody (#05-6γ6, Millipore) for 18 h at 4 °C. This 
 11
was followed by incubation with anti-IgG-Alexa568 (#A110γ1, Invitrogen). Coverslips 
were then washed in 4% DAPI/1X PBS and mounted with ProLong® gold antifade 
mounting solution (Invitrogen). Slides were imaged using a Zeiss LSM 510 confocal 
microscope. Per condition, a minimum of γ00 cells were counted and quantified for 
けHβAX positive cells (> 5 foci per nucleus).   
 
Statistical analysis 
Unless otherwise stated, data represent standard error of the mean of at least three 
independent experiments. The two-tailed paired Student’s t test was used to determine 
statistical significant with p<0.05 regarded as significant. For confocal experiments, 
images are representative of at least three independent experiments, where a minimum 
of γ00 cells were analyzed. 
 
Results 
MMR deficiency increases the toxicity of triamterene in a range of tumor-derived 
cell lines  
To identify compounds that can sensitize MMR-deficient cells, we screened a large 
panel of cell lines with a range of different MMR gene mutations from a number of tumor 
types. These included the MSH6-deficient colorectal cancer cell line DLD1 and its 
isogenic MSH6-proficient DLD1+Chrβ cell line (Figure 1A), the previously characterized 
temozolomide-resistant MSH6-deficient Uβ51.TRγ GBM cell line and the isogenic 
MSH6-proficient Uβ51 cell line (Figure 1B; (5, 16)) and a panel of endometrial cancer cell 
lines; KLE (MMR-proficient), MFE-β80 (MMR-proficient), MFE-β96 (MLH1-deficient), 
ISHIKAWA (MLH1-deficient) and HEC1B (MSH6-deficient; Figure 1C).   
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Based on the concept of drug repositioning, of identifying previously approved 
compounds for new clinical indications, cells were screened in the presence of either 
vehicle (DMSO) or a compound library comprising 1018 FDA-approved drugs. This 
approach aimed to identify compounds with previous unknown potential for repurposing 
as MMR-selective drugs. Analysis of our screens revealed that the potassium-sparing 
diuretic compound, Triamterene was a promising candidate for a new MMR-selective 
drug. Validation experiments revealed that, although the sensitization was variable 
depending on the MMR-defect, however when compared to the MMR-proficient cells, 
treatment with Triamterene induced toxicity over a range of concentrations specifically in 
MMR-deficient cells (Figure 1D-F). Triamterene also caused sensitivity in MMR-deficient 
cells, in comparison to MMR-proficient cells, in a clonogenic survival assay (Figure 1G). 
 
To further investigate this selectivity for MMR deficiency, we measured cell viability of 
the MLH1-deficient colorectal cancer cell line HCT116 and its isogenic matched-paired 
MLH1-proficient cell line, HCT116+Chrγ when treated with Triamterene (Figure 1H). 
Significantly, Triamterene also induced selectivity in the MLH1-deficient HCT116 cells, 
but not in MLH1-proficient cells. Significantly, we observed selectivity in all MMR 
deficient cell lines tested, regardless of MMR mutation or tumor type, while no significant 
effect was observed in MMR-proficient cells. This suggests that Triamterene is selective 
with loss of MMR pathway function and may provide a novel therapeutic strategy in a 
wide range of cancers. 
 
Triamterene cytotoxicity occurs through its antifolate activity and requires 
thymidylate synthase expression 
Previous studies have shown that Triamterene can act as both an inhibitor of the 
epithelial sodium channel (ENaC) (17) and also as an antifolate (18). Therefore, to 
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determine the mechanism underlying the observed Triamterene-induced cytotoxicity with 
MMR-deficiency, we performed siRNA-mediated depletion of a panel of ENaC isoforms 
(α, β & γ) previously suggested to be inhibited by Triamterene and analyzed cell viability 
(Figure βA). We observed no differential cytotoxicity upon targeting the ENaC isoforms, 
either alone or in combination, which suggests that the observed selectivity is not due to 
ENaC inhibition. We next determined whether Triamterene-mediated selectivity was due 
to its anti-folate activity. To this end, we measured the cell viability of MMR-deficient and 
proficient cells treated with folates (dihydrofolate and tetrahydrofolate) in addition to 
Triamterene. We observed that the selectivity of Triamterene for MMR deficiency could 
be rescued by the addition of folates (Figure βB & βC), therefore suggesting that 
Triamterene is selective through its anti-folate activity.  
 
To further analyze the anti-folate effect of Triamterene, we analyzed the requirement for 
thymidylate synthase in Triamterene-mediated selectivity. Thymidylate synthase is the 
only de novo enzyme for dTMP synthesis. It catalyzes the reductive transfer of a methyl 
group from N5,N10-methylenetetrahydrofolate (CHβ-THF) to dUMP, forming dTMP and 
dihydrofolate (DHF). Our results suggest that thymidylate synthase protein expression is 
not altered upon Triamterene treatment (Figure βD). However, silencing thymidylate 
synthase by siRNA prevents Triamterene-induced lethality in MMR-deficient cells (Figure 
βE & βF; Supplementary Figure 1A). These results suggest that thymidylate synthase 
expression is necessary for the Triamterene-mediated selectivity in MMR-deficient cells. 
Furthermore, treatment with the clinically approved thymidylate synthase inhibitors, 5-FU 
and Raltitrexed, also rescued the Triamterene-induced cytotoxicity in MMR-deficient 
cells (Supplementary Figure 1B). Taken together, our results suggest that Triamterene-
induced selectivity is due to the anti-folate activity of Triamterene and is dependent on 
thymidylate synthase expression.  
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Triamterene-induced cytotoxicity depends on increased ROS levels 
It has previously been shown that folate starvation can increase ROS levels, leading to 
cellular oxidative stress (19). Our previous studies have shown that an increase in 
oxidative stress is synthetically lethal with MMR deficiency (9, 10, 14, 15). Therefore, we 
investigated whether Triamterene can induce an increase in ROS levels due to folate 
inhibition in MMR-deficient and -proficient cells. To this end, we treated MMR-deficient 
and -proficient cells with increasing concentrations of Triamterene and measured ROS 
levels (Figure γA & B). Our results show a greater increase in the level of ROS in 
Triamterene-treated MMR-deficient cells, in comparison to MMR-proficient cells. To 
further investigate if this increase in ROS levels in MMR-deficient cells was responsible 
for Triamterene selectivity, we treated cells with Triamterene alone or in combination 
with the ROS scavenger, N-acetylcysteine (NAC; Figure γC). Our results demonstrate 
that the Triamterene-induced selectivity in MMR-deficient cells can be rescued by 
addition of NAC, which suggests that increased ROS levels are, at least in part, the 
mechanism of toxicity upon Triamterene treatment. Our data indicates the importance of 
thymidylate synthase expression in triamterene-induced selectivity. To further investigate 
this, we analyzed ROS levels upon thymidylate synthase silencing and Triamterene 
treatment (Figure γD & E). Interestingly, we observed that silencing thymidylate 
synthase by siRNA prevents the Triamterene-induced increase in ROS levels. These 
results suggest that thymidylate synthase is required for ROS accumulation, leading to 
Triamterene cytotoxicity.  
 
Our results suggest that MMR-deficient cells have reduced cellular viability upon 
Triamterene treatment. To investigate the mechanism of this selectivity further, we 
stained cells, before and after Triamterene treatment, with propidium iodide and 
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measured cells by flow cytometry to determine which phase of the cell cycle they 
accumulated in after treatment (Figure 4A). Interestingly, our results suggest that upon 
Triamterene treatment, MMR-deficient cells arrest in the Gβ/M phase of the cell cycle, 
corresponding to the reduced cellular viability we observed. An increase in ROS levels 
can lead to cellular DNA damage, including DNA single-strand breaks, alkali-labile sites, 
oxidative DNA damage and ultimately an increase in DNA double strand breaks (DSB), 
thereby triggering cell cycle arrest. To assess if Triamterene induces DNA damage in 
MMR-deficient cells, we measured cellular DNA damage including DNA fragmentation 
and DNA strand breaks using the comet assay (Figure 4B). Treatment with Triamterene 
resulted in an increase in DNA damage in the MMR-deficient cells only. To further 
investigate the type of DNA damage induced, we measured accumulation of the 
oxidative DNA lesion, 8-Oxo-β'-deoxyguanosine (8฀oxodG) using an ELISA assay 
(Figure 4C). We observed a significant increase in 8฀oxodG DNA lesions in the 
Triamterene-treated MMR-deficient cells only. To determine whether this oxidatively 
damaged DNA, resulted in DNA double strand breaks triggering cell cycle arrest, we 
measured けHβAX foci, a marker for DNA DSBs, by confocal microscopy (Figure 5A-D). 
Treatment with Triamterene induced an increase in けHβAX foci in MMR-deficient cells, 
which can be rescued by addition of the ROS scavenger, NAC. Taken together, our 
results suggest that Triamterene treatment leads to an increase in ROS levels in MMR-
deficient cells, which ultimately leads to an increase in 8-oxodG DNA lesions and DNA 
DSBs, resulting in cell cycle arrest (Figure 4D).  
 
Triamterene can re-sensitize MMR-deficient cells in vivo 
To examine the in vivo efficacy of Triamterene, the MMR-deficient and MMR-proficient 
DLD1 and DLD1+Chrβ, respectively, colorectal cancer cells, were injected 
subcutaneously into NOD-SCID mice. Xenografted mice were subjected to treatment γ 
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times a week with Triamterene or vehicle (PBS). We observed that tumor growth from 
the MMR-deficient xenografts was significantly reduced (p=0.01) by Triamterene 
treatment when compared to vehicle (Figure 6A). In addition, no difference in tumor 
growth was observed in the Triamterene treated MMR-proficient xenograft tumors when 
compared to vehicle, further validating Triamterene as a compound that specifically 
targets cancer cells with deficient MMR pathways (Figure 6B). Taken together, these in 
vivo observations further indicate that Triamterene treatment has potential clinical utility 
in patients with MMR-deficient, for which therapeutic options are scarce. 
 
DISCUSSION 
Through a compound screen, we identified the diuretic drug Triamterene as an in vitro 
and in vivo selective compound with MMR deficiency. Collectively, our data argues that 
stratifying patients according to their MMR status would prove efficacious with regards to 
treatment with Triamterene. Furthermore, our data suggests that levels of thymidylate 
synthase govern sensitivity to Triamterene in MMR-deficient cells. Upon thymidylate 
synthase inhibition, treatment with Triamterene was no longer selective suggesting that 
thymidylate synthase levels determine the balance between Triamterene resistance and 
sensitivity in these cells. Our data suggest that folate inhibition and thymidylate synthase 
are critical for the triamterene selectivity in MMR-deficient cells, however we cannot 
exclude the fact that other pathways may also be influencing this effect, at least in part. 
One of the most intriguing findings from this work is the requirement for thymidylate 
synthase for the induction of ROS upon Triamterene treatment. It is likely due to an 
activity of thymidylate synthase in the absence of sufficient levels of methyl donor CHβ-
THF, thus leading to ROS. It would be interesting to understand whether thymidylate 
synthase is regulating ROS levels through NAPDH oxidase complexes or providing 
protection against ROS production through the antioxidant response. Numerous studies 
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have investigated ROS induction upon treatment with thymidylate synthase inhibitors, 
but, to our knowledge, no study has identified a role for thymidylate synthase in the 
regulation of ROS levels. Previously, antifolate agents targeting the folate metabolic 
enzyme dihydrofolate reductase (DHFR), such as methotrexate and pemetrexed, were 
identified as cytotoxic in MSHβ-deficient cells, but not in other MMR-deficient cell lines 
(9, 20). Perhaps this is due to the generation of specific DNA lesions upon DHFR 
inhibition in MSHβ-deficient cells, rather than a more general inhibition of folate 
metabolism upon Triamterene treatment. Taken together, these data also suggest a 
potential difference in the folate metabolic pathway in MMR-deficient and -proficient cell 
lines.  
 
An increase in ROS levels can lead to cellular DNA damage, including DNA 
fragmentation, oxidative DNA damage and ultimately an increase in DNA double strand 
breaks (DSB), thereby triggering cell cycle arrest. We observed a significant increase in 
cellular DNA damage, and more specifically 8-oxodG DNA lesions in the Triamterene-
treated MMR-deficient cells only. Our data suggest that these lesions, if incompletely 
repaired, can induce DNA DSBs, which ultimately result in the cell cycle arrest and 
reduced cellular viability we observe.  
 
We and others have focused largely on targeting loss of DNA repair in tumor cells. 
However, recent advances indicate that targeting both the tumor cell and its interaction 
with the immune microenvironment may significantly improve patient benefit. A recent 
Phase II clinical trial in patients with deficiency in the MMR pathway indicated that MMR 
status predicted clinical benefit with the PD-1 inhibitor pembrolizumab (21). However, 
only 50% of MMR-deficient patients responded to pembrolizumab, suggesting that 
selectively targeting MMR-deficient tumor cells with for example Triamterene, in 
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combination with immune checkpoint inhibitors may increase therapeutic efficacy and 
may prove to be more clinically beneficial.  
 
In this study we exploit the concept of drug repurposing, which is the discovery of new 
indications for existing drugs, to identify novel selective drugs for the treatment of MMR-
deficient tumors. Repositioning of drugs highlights an increasingly effective means of 
drug discovery. In addition to the reduced cost and time commonly associated with 
traditional drug discovery, the advantage of drug repositioning strategies is the fact that 
existing drugs have already been used in patients and, therefore, their toxicity and safety 
profiles are already established. Hence, drugs identified in drug repositioning 
approaches can enter clinical trials rapidly, thereby maximizing their potential benefit to 
patients. Here, we have shown for the first time that Triamterene, originally developed as 
a diuretic, has anti-tumor activity and we provide evidence of its efficacy in a range of 
MMR-deficient tumor types. 
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FIGURE 1. Triamterene sensitizes MMR-deficient cells 
(A) Western blot analysis of protein lysates from DLD1 and DLD1+Chrβ cells. Protein 
expression was measured using MSH6 and く-actin antibodies. く-actin was used as a 
loading control. 
(B) Western blot analysis of protein lysates from Uβ51 and Uβ51.TRγ cells. Protein 
expression was measured using MSH6 and く-actin antibodies. く-actin was used as a 
loading control. 
(C) Western blot analysis of protein lysates from a panel of MMR-proficient (KLE, MFE-
β80) and MMR-deficient (ANγCA, MFE-β96, ISHIKAWA, HEC1B, HEC59, RL95-β) 
endometrial cancer cell lines. Protein expression was measured using indicated 
antibodies. く-tubulin was used as a loading control. 
(D) MSH6-proficient DLD1+Chrβ and MSH6-deficient DLD1 colorectal cell lines were 
treated with increasing concentrations of Triamterene (0, β µM, 4 µM, 6 µM, 8 µM & 10 
µM). After 4 days treatment, cell viability was measured using an ATP-based 
luminescence assay. 
(E) MSH6-proficient Uβ51 and MSH6-deficient Uβ51.TRγ cells were treated with 
increasing concentrations of Triamterene (0, 5 µM, 10 µM, 15 µM & β0 µM). After 4 days 
treatment, cell viability was measured using an ATP-based luminescence assay. 
(F) A panel of MMR-proficient (KLE, MFE-β80) and MMR-deficient (ANγCA, MFE-β96, 
ISHIKAWA, HEC1B, HEC59, RL95-β,) endometrial cancer cell lines were treated with 
increasing concentrations of Triamterene (0, 10 µM, β0 µM, γ0 µM & 40 µM). After 4 
days treatment, cell viability was measured using an ATP-based luminescence assay. 
(G) MSH6-proficient DLD1+Chrβ and MSH6-deficient DLD1 colorectal cell lines were 
treated with Triamterene (0, 8 µM & 10 µM). After 10-14 days treatment, cell survival 
was measured by counting sulphorhodamine‐B stained colonies. 
(H) MLH1-proficient HCT116+Chrγ and MLH1-deficient HCT116 colorectal cancer cell 
lines were treated with increasing concentrations of Triamterene (0, β µM, 4 µM, 6 µM, 8 
µM & 10 µM). After 4 days treatment, cell viability was measured using an ATP-based 
luminescence assay.  
D-H: Data represent mean ± SEM of three independent experiments.  
 
 ββ
FIGURE 2. Triamterene is selective via its anti-folate activity and requires 
thymidylate synthase expression 
(A) MSH6-proficient Uβ51 and MSH6-deficient Uβ51.TRγ GBM cells were transfected 
with either control non-targeting siRNA (siCTRL) or siRNA targeting the different 
isoforms of the epithelial sodium channel, ENaC (α, β & γ), either alone or in 
combination. 4 days post transfection, cell viability was measured using an ATP-based 
luminescence assay.  
(B) Uβ51 and Uβ51.TRγ GBM cells were treated with either Control (DMSO; 0.01%), 
Triamterene (β0 µM), Dihydrofolate (DHF; 10 µM), Tetrahydrofolate (THF; 10 µM) alone 
or combinations of DHF (10 µM) or THF (10 µM) with Triamterene (β0 µM). After 4 days 
treatment, cell viability was measured using an ATP-based luminescence assay. 
**p<0.0001 
(C) DLD1 and DLD1+Chrβ cells were treated with either media or Triamterene (10 µM), 
alone or in combination with dihydrofolate (DHF; 10 µM) or tetrahydrofolate (THF; 10 
µM). After 4 days treatment, cell viability was measured using an ATP-based 
luminescence assay. **p≤0.007. 
(D) Western blot analysis of protein lysates from Uβ51 and Uβ51.TRγ cells treated with 
either DMSO (0.01%) or Triamterene (10 µM) for 48 hrs. Protein expression was 
analysed using anti-TS (thymidylate synthase) and く-actin antibodies. く-actin was used 
as a loading control. 
(E) Uβ51 and Uβ51.TRγ cells were transfected with control non-targeting siRNA 
(siCTRL) or siRNA targeting thymidylate synthase (siTS*1, siTS*β). After β4 hrs, cells 
were treated with either DMSO (0.01%) or increasing concentrations of Triamterene (0, 
4 µM, 8 µM, 1β µM, 16 µM & β0 µM). After 4 days treatment, cell viability was measured 
using an ATP-based luminescence assay. *p=0.00β5, **p=0.0001. 
(F) DLD1 and DLD1+Chrβ cells were transfected with either control non-targeting siRNA 
(siCTRL) or siRNA targeting thymidylate synthase (siTS*1, siTS*β). After β4 hrs, cells 
were treated with either DMSO (0.01%) or increasing concentrations of Triamterene (0, 
β µM, 4 µM, 6 µM, 8 µM & 10 µM). After 4 days treatment, cell viability was measured 
using an ATP-based luminescence assay. *p≤0.01. 
 
A-C, E & F: Data represent mean ± SEM of three independent experiments. 
 
FIGURE 3. Triamterene treatment induces ROS in MMR-deficient cells  
 βγ
(A) Uβ51 and Uβ51.TRγ GBM cells were treated with either Control (DMSO; 0.01%), 10 
µM or β0 µM Triamterene. After 48 hrs treatment, ROS levels were measured by 
quantifying the conversion of DCFDA into DCF by fluorescence. Fluorescence data were 
normalized to cell viability. *p≤0.04 
(B) DLD1 and DLD1+Chrβ cells were treated with either Control (DMSO; 0.01%), 5 µM 
or 10 µM Triamterene. After 48 hrs treatment, ROS levels were measured by quantifying 
the conversion of DCFDA into DCF by fluorescence. Fluorescence data were normalized 
to cell viability. ***p≤0.0006. 
(C) DLD1 and DLD1+Chrβ cells were treated with either Control (DMSO; 0.01%), or 
increasing concentrations of Triamterene (0, β µM, 4 µM, 6 µM, 8 µM & 10 µM) alone or 
in combination with the ROS scavenger N-Acetyl cysteine (NAC; 1 mg/mL). After 4 days 
treatment, cell viability was measured using an ATP-based luminescence assay. 
*p=0.0γ, **p≤0.004. 
(D) Uβ51 and Uβ51.TRγ cells were transfected with either control non-targeting siRNA 
(siCTRL) or siRNA targeting thymidylate synthase (siTS*1, siTS*β). After β4 h, cells 
were treated with either DMSO (0.01%) or Triamterene (β0 µM). After 48 h treatment, 
ROS levels were measured by quantifying the conversion of DCFDA into DCF by 
fluorescence. Fluorescence data were normalized to cell viability. **p≤0.007. 
(E) DLD1 and DLD1+Chrβ cells were transfected with either control, non-targeting 
siRNA (siCTRL) or siRNA targeting thymidylate synthase (siTS*1, siTS*β). After β4 hrs, 
cells were treated with either DMSO (0.01%) or Triamterene (10 µM). After 48 hrs 
treatment, ROS levels were measured by quantifying the conversion of DCFDA into DCF 
by fluorescence. Fluorescence data were normalized to cell viability. **p≤0.00β. 
A- E: Data represent mean ± SEM of three independent experiments. 
 
FIGURE 4. Triamterene treatment induces cellular DNA damage and G2/M arrest in 
MMR-deficient cells 
(A) DLD1 and DLD1+Chrβ cells were treated with either Control (DMSO; 0.01%), or 
Triamterene (10 µM). FACS analysis was performed β4 h after Triamterene treatment. 
Data was normalized to initial numbers of cells in the Gβ/M phase of the cell cycle. 
Assays were performed in triplicate and bar chart shows the fold change in cells in the 
Gβ/M phase of the cell cycle in each cell line. **p≤0.001. 
(B) DLD1 and DLD1+Chrβ cells were treated with either Control (DMSO; 0.01%), or 
Triamterene (10 µM). After 48 h cells were mixed with molten agarose, DNA was 
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denatured and electrophoresed in a horizontal chamber. Stained DNA was visualized by 
fluorescence microscopy. Cellular DNA damage was visualised as a comet tail shape. 
Assays were performed in triplicate and bar chart shows the % of tail DNA observed in 
each cell line. ***p≤0.0001. 
(C) DLD1 and DLD1+Chrβ cells were treated with either Control (DMSO; 0.01%), or 
Triamterene (10 µM). After 48 h, DNA was extracted and 8-oxodG was quantified 
according to a standard curve. Assays were performed in triplicate and bar chart shows 
the fold change in 8-oxodG lesions in each cell line. *p≤0.01. 
(D) Schematic model of the sensitizing effect of Triamterene in MMR-deficient cells 
 
FIGURE 5. Triamterene treatment induces DNA DSBs in MMR-deficient cells, 
which can be rescued by addition of N-Acetyl cysteine 
(A) Representative images of けHβAX foci, quantified by confocal microscopy in Uβ51 
and Uβ51.TRγ cells upon treatment with either PBS or NAC (10 mg/mL) alone or in 
combination with DMSO (0.01%) or Triamterene (β0 µM). Nuclei are shown in blue 
(DAPI) and けHβAX foci are in red. 
(B) DLD1 and DLD1+Chrβ cells were treated with either PBS or NAC (10 mg/mL) alone 
or in combination with DMSO (0.01%) or Triamterene (10 µM). After 48 hrs treatment, 
cells were fixed, stained using a けHβAX antibody and DAPI, and observed by confocal 
microscopy. Per condition, a minimum of γ00 cells were counted and quantified for 
けHβAX positive cells (> 5 foci per nucleus). ***p≤0.0001. 
(C) Uβ51 and Uβ51.TRγ cells were treated with either Control (DMSO; 0.01%), 
Triamterene (β0 µM) or NAC (10 mg/mL) alone or in combination. After β4 hrs treatment, 
cells were fixed, stained using a けHβAX antibody and DAPI and observed by confocal 
microscopy. Per condition, a minimum of γ00 cells were counted and quantified for 
けHβAX positive cells (> 5 foci per nucleus).  ***p≤0.0008. 
(D) Representative images of けHβAX foci, quantified by confocal microscopy in DLD1 
and DLD1+Chrβ cells upon treatment with either PBS or NAC (10 mg/mL) alone or in 
combination with DMSO (0.01%) or Triamterene (10 µM). Nuclei are shown in blue 
(DAPI) and けHβAX foci are in red. 
 
FIGURE 6. Triamterene sensitizes MMR-deficient cells, in vivo  
In vivo efficacy experiments were performed on β0 NOD-SCID mice injected with either 
DLD1 cells (A; 1.6 x 106 cells) or DLD1+Chrβ cells (B; 1.6 x 106 cells). When the tumors 
 β5
were measurable, mice were treated γ times a week by gavage with β5 mg/kg 
Triamterene or vehicle. Tumors were measured twice a week and tumor size was 
normalized to initial treatment measurements. Data represent mean ± SEM. **p=0.01. 
NS denotes a p >0.05. 
 






